



Australian Government

Department of Health

**SCHEDULE OF PHARMACEUTICAL
BENEFITS**

**EFFICIENT FUNDING OF CHEMOTHERAPY
SECTION 100 – ARRANGEMENTS SUPPLEMENT**

SUMMARY OF CHANGES

EFFECTIVE 1 December 2013

SUMMARY OF CHANGES

Deletions

Deletion – Restriction

7248L **Ifosfamide**, (*Holoxan, Holoxan*)

4448D **Ifosfamide**, (*Holoxan, Holoxan*)

Advance Notices

Advance Notices – Deletion of Brand

The following brands will be deleted from the Schedule of Pharmaceutical Benefits on 1 March 2014:

4309T *Pfizer Australia Pty Ltd, PF* – **Carboplatin**, carboplatin 150 mg/15 mL injection, 1 x 15 mL vial

7222D *Pfizer Australia Pty Ltd, PF* – **Carboplatin**, carboplatin 150 mg/15 mL injection, 1 x 15 mL vial

4319H *Pfizer Australia Pty Ltd, PF* – **Cisplatin**, cisplatin 50 mg/50 mL injection, 1 x 50 mL vial

7224F *Pfizer Australia Pty Ltd, PF* – **Cisplatin**, cisplatin 50 mg/50 mL injection, 1 x 50 mL vial

4319H *Pfizer Australia Pty Ltd, PF* – **Cisplatin**, cisplatin 100 mg/100 mL injection, 1 x 100 mL vial

7224F *Pfizer Australia Pty Ltd, PF* – **Cisplatin**, cisplatin 100 mg/100 mL injection, 1 x 100 mL vial

4514N *Pfizer Australia Pty Ltd, PF* – **Mitozantrone**, mitozantrone 20 mg/10 mL injection, 1 x 10 mL vial

7252Q *Pfizer Australia Pty Ltd, PF* – **Mitozantrone**, mitozantrone 20 mg/10 mL injection, 1 x 10 mL vial